김동욱

논문

• 1. Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities and Molecular Responses in Asian Patients With Chronic Myeloid Leukemia, Clinical Lymphoma Myeloma and Leukemia 2021, Jun;21(6):e521-e529. doi: 10.1016/j.clml.2021.01.020. Epub 2021 Feb 2./Corresponding author
  
  2. Change of right ventricular systolic pressure can indicate dasatinib-induced pulmonary arterial hypertension in chronic myeloid leukemia, Cancer Medicine, 2021 Mar;10(5):1515-1524. doi: 10.1002/cam4.3588. Epub 2021 Feb 15./Corresponding author
  
  3. Prognosis Score System to Predict Survival for COVID-19 Cases: a Korean Nationwide Cohort Study, Journal of Medical Internet Research, 2021 Feb 22;23(2):e26257. doi: 10.2196/26257./Corresponding author
  
  4. Lymphopenia as a Biological Predictor of Outcomes in COVID-19 Patients: A Nationwide Cohort Study, Cancers (Basel), 2021 Jan 26;13(3):471. doi: 10.3390/cancers13030471./Corresponding author
  
  5. Development of a dried blood spot sampling method towards therapeutic monitoring of radotinib in the treatment of chronic myeloid leukaemia, Journal of Clinical Pharmacy and Therapeutics, 2020 Oct;45(5):1006-1013. doi: 10.1111/jcpt.13124. Epub 2020 Feb 5./Corresponding author
  
  6. Successful Prevention and Screening Strategies for COVID-19: Focused on Patients With Hematologic Diseases., British Journal of Haematology, 2020 Jul;190(1):e33-e37. doi: 10.1111/bjh.16818. Epub 2020 Jun 1./Corresponding author
  
  7. Nilotinib-Induced Immune-Mediated Liver Injury: Corticosteroid as a Possible Therapeutic Option, Frontiers in Oncology, 2020 Jul 10;10:1160. doi: 10.3389/fonc.2020.01160./Corresponding author
  
  8. Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE), British Journal of Haematology, 2020 Apr;189(2):303-312. doi: 10.1111/bjh.16381. Epub 2020 Feb 3./Corresponding author
  
  9. Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia, International Journal of Hematology, 2020 Mar;111(3):417-426. doi: 10.1007/s12185-019-02805-9. Epub 2019 Dec 20./Corresponding author
  
  10. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure., New England Journal of Medicine, 2019 Dec 12;381(24):2315-2326. doi: 10.1056/NEJMoa1902328./Corresponding author
  
  11. GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia, Autophagy, 2019 Dec;15(12):2076-2090. doi: 10.1080/15548627.2019.1596492. Epub 2019 Mar 30./Corresponding author
  
  12. Optimal Time Points for BCR-ABL1 Tyrosine Kinase Domain Mutation Analysis on the Basis of European LeukemiaNet Recommendations in Chronic Myeloid Leukemia, Clinical Lymphoma Myeloma & Leukemia, 2019 Jul;19(7):406-412.e1. doi: 10.1016/j.clml.2019.02.003. Epub 2019 Feb 20./Corresponding author
  
  13. Compound mutations involving T315I and P-loop mutations are the major components of multiple mutations detected in tyrosine kinase inhibitor resistant chronic myeloid leukemia, Leukemia Research, 2019 Jan;76:87-93. doi: 10.1016/j.leukres.2018.10.019. Epub 2018 Nov 27./Corresponding author
  
  14. Comparison of Frequency and Sensitivity of BCR-ABL1 Kinase Domain Mutations in Asian and White Patients With Imatinib-resistant Chronic-Phase Chronic Myeloid Leukemia, Clinical Lymphoma Myeloma & Leukemia, 2018 Oct;18(10):e391-e399. doi: 10.1016/j.clml.2018.06.031. Epub 2018 Jul 4./Corresponding author
  
  15. BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors, Cancer Medicine, 2018 Oct;7(10):5107-5117. doi: 10.1002/cam4.1753. Epub 2018 Aug 31./Corresponding author
  
  16. Outcomes of switching to dasatinib after imatinib-related low grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study, Annals of Hematology, 2018 Aug;97(8):1357-1367. doi: 10.1007/s00277-018-3295-8. Epub 2018 Mar 20./First&Corresponding author
  
  17. Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia, Cancer Medicine, 2018 May;7(5):1766-1773. doi: 10.1002/cam4.1436. Epub 2018 Mar 25./Corresponding author
  
  18. Phase III clinical trial (RERISE study) results of Efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia, Clinical Cancer Research, 2017 Dec 1;23(23):7180-7188. doi: 10.1158/1078-0432.CCR-17-0957. Epub 2017 Sep 22./Corresponding author
  
  19. Cobll1: A new player in CML, Oncotarget, 2017 Oct 10;8(53):90626-90627. doi: 10.18632/oncotarget.21705. eCollection 2017 Oct 31./Corresponding author
  
  20. Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia, Leukemia, 2017 Jul;31(7):1532-1539. doi: 10.1038/leu.2017.72. Epub 2017 Feb 24./Corresponding author